Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234

Limited treatment options exist to combat infections caused by multidrug-resistant (MDR) Gram-negative bacteria possessing broad-spectrum β-lactamases. The design of novel β-lactamase inhibitors is of paramount importance. Here, three novel diazabicyclooctanes (DBOs), WCK 5153, zidebactam (WCK 5107)...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Med Chem
Egile Nagusiak: Papp-Wallace, Krisztina M., Nguyen, Nhu Q., Jacobs, Michael R., Bethel, Christopher R., Barnes, Melissa D., Kumar, Vijay, Bajaksouzian, Saralee, Rudin, Susan D., Rather, Philip N., Bhavsar, Satish, Ravikumar, Tadiparthi, Deshpande, Prasad K., Patil, Vijay, Yeole, Ravindra, Bhagwat, Sachin S., Patel, Mahesh V., van den Akker, Focco, Bonomo, Robert A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6131718/
https://ncbi.nlm.nih.gov/pubmed/29627985
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.8b00091
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak